[Preventive effect of captopril on the development of genetic hypertension in SHR rats (author's transl)].
Captopril, an inhibitor of the angiotensin-converting enzyme, is very effective in preventing the development of genetic hypertension in SHR rats. This effect results from early, overall lowering of local vascular resistances and, consequently, suppression of the age-related increase in total peripheral resistance. Contrary to that of dihydralazine and atenolol, it persists for up to 12 weeks after the drug is discontinued. Captopril may act by inhibiting the angiotensin-converting enzyme present in the vascular wall, with subsequent temporary arrest of the vascular lesions associated with progressive genetic hypertension.
D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D001808:Blood Vessels / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology / Q000627:therapeutic use*; D006332:Cardiomegaly / Q000517:prevention & control; D006973:Hypertension / Q000235:genetics / Q000517:prevention & control*; D011392:Proline / Q000031:analogs & derivatives*; D051381:Rats; D014655:Vascular Resistance / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D011392:Proline; D002216:Captopril
Captopril et prévention du développement de l'hypertension génétique du rat SHR.